Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment

cafead

Administrator
Staff member
  • cafead   Jul 17, 2018 at 10:12: AM
via Eureka Therapeutics Inc. announced on 7/17/18 that Boehringer Ingelheim has elected to exercise an option for the exclusive license of novel human TCR-mimicking (TCRm) antibodies against an undisclosed target to be used for the potential development and commercialization of therapies for cancer patients.

article source
 

<